Barclays’s Ascendis Pharma A/S ASND Stock Holding History

Barclays’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-72,500	Closed	-$11M	–	4859
2024 Q1	$11M	Buy	72,500 +50,000	+222%	+$7.14M	﹤0.01%	1325
2023 Q4	$2.83M	Buy	+22,500	New	+$2.24M	﹤0.01%	2624
2021 Q4	–	Sell	-38,300	Closed	-$6.11M	–	4117
2021 Q3	$6.11M	Buy	+38,300	New	+$5.24M	﹤0.01%	1495
2019 Q2	–	Sell	-67,000	Closed	-$7.89M	–	6924
2019 Q1	$7.89M	Buy	67,000 +28,900	+76%	+$2.53M	0.01%	1374
2018 Q4	$2.39M	Buy	+38,100	New	+$2.39M	﹤0.01%	2233

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Barclays's ASND Position: Q2 2026 in Review

Barclays increased its Ascendis Pharma A/S (ASND) stake by 116% in Q2 2026, buying an estimated $9.6M and bringing the position to 76,540 shares worth $20.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1121.

Barclays first reported a position in ASND in Q3 2017 and has held it in 36 quarters since. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Barclays held 76,540 shares of Ascendis Pharma A/S worth $20.4M as of Q2 2026.
Barclays bought 41,087 Ascendis Pharma A/S shares in Q2 2026, an estimated $9.6M.
Ascendis Pharma A/S made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1121 holding.
Barclays first reported a position in Ascendis Pharma A/S in Q3 2017 and has held it in 36 quarters since.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.